Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AZ-004
AZ-004
Biotech Calendar: 2011-12 FDA Drug Approvals
TheStreet.com
Thu, 08/11/11 - 12:37 pm
biotech
drug approvals
FDA
Eyelea
Regeneron
Dendreon
Provenge
NuPathe
Zelrix
Adcetris
Seattle Genetics
Soliris
Alexion
Dapagliflozin
AstraZeneca
Bristol-Myers Squibb
EXPAREL
Pacira
Roche
Zelboraf
Iluvien
Alimera
Bio-T-Gel
Teva Pharmaceuticals
BioSante
Zevalin
Spectrum
ruxolitinib
Incyte
Novartis
Pfizer
crizotinib
Antares
Anturol
Bydureon
Amlyin
Eli Lilly
Alkermes
AZ-004
Alexza
Corlux
Corcept Therapeutics
Affymax
Takeda
peginesatide
Levadex
MAP Pharmaceuticals
Biotech Calendar: Key Dates for August
TheStreet.com
Tue, 08/2/11 - 12:29 pm
Alexa
Gilead Sciences
Regeneron
Dendreon
NuPathe
Provenge
Adcetris
Seattle Genetics
Eyelea
Btripla
Zelrix
AZ-004
All Eyes on Alexza as Company Prepares to Re-File Drug Application
Seeking Alpha
Wed, 03/16/11 - 04:43 pm
Alexza
bipolar disorder
schizophrenia
AZ-004
Staccato Loxapine
Alexza shares tumble on FDA setback
Marketwatch
Tue, 01/18/11 - 11:21 am
Alexza
FDA
AZ-004
bipolar disorder
schizophrenia
Risks vs. Benefits in Holding Alexza Through Approval of AZ-004
Seeking Alpha
Mon, 10/11/10 - 10:59 am
Alexza
AZ-004
Biovail
